創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
19/10/04 GEM112 Antibody against H.Pylori-derived HSP60 Eradication of H.Pylori i.v. Protein
Preclinical Antibiotic-resistance H.Pylori are getting serious and antibiotic therapy failure rate is over 20%. GEM112 is a highly specific antibody against H.Pylori-derived HSP60 which inhibits T cell proliferation and induces IL-10 and TGF-b1. GEM112 does not bind to human HSP60. 問合せ
19/09/30 GEM111 c-RAF allosteric inhibitor Refer to Note Oral Small molecule
IND Indication:
Multiple cancers (lung, renal, liver etc)

Note:
A second generation (novel salt) of the c-RAF allosteric inhibitor in GEM 110 allowing for a more patient-centric dose profile. The clinical safety profile of GEM110 thus far will be informative and additive to the current clinical program thereby significantly de-risk and accelerate the clinical stage development of GEM111.
問合せ
19/09/30 GEM110 c-RAF allosteric inhibitor Refer to Note Oral Small molecule
Phase I Indication:
Multiple cancers (lung, renal, liver etc)

Note:
The product is the combination of GEM110 and sorafenib.
The product induces pDAPK and c-Raf to transfer from mitochondria to cytoplasm together with ROS increment resulting tumor cell death and demonstrated 73% and 57% tumor inhibition rate respectively in lung cancer and renal cancer animal xenograft model.
FDA approved the clinical protocol to explore subjects by p-DAPK biomarker whose expressin could be related with tumor progression.
問合せ
19/09/30 GEM109 Refer to Note Hematological malignancies Infusion Cell Therapy
Preclinical Mechanism of action:
Expanded Hematopoetic stem cells for transplantation without HLA match

Note:
Propreitray technology that allows hematopoietic stem cell expansion for transplantation for hematological malignancies (leukemia, lymphoma) without the need of HLA match.
Successfully completed POC studies.
問合せ
19/09/30 GEM108 Buccal Epithelial cells for re-epithelization Urethral Strictures Refer to Note Cell Therapy
Phase IIb completed Route:
Implantation

Note:
Live cultured buccal epitherial cells indicated for urethral strictures. Excellent safety and efficacy profiles have been established through Phase IIb clinical trials. Potential label extension to rare disease in pediatric population; hypospadias.
問合せ
19/09/30 GEM107 Chondrocytes for hyaline cartialge regeneration. Articular cartilage defects Refer to Note Cell Therapy
Launch Route:
Interventional/ Implantation

Note:
Live cultured chondrocytes indicated for hyaline cartilage reneration in cartilage injuries. Over 600 pateints treated with several publications and patent protection.
問合せ
19/09/30 GEM106 Osteoblasts for bone regeneration Refer to Note Refer to Note Cell Therapy
Launch Indication:
Avascular necrosis/Osteonecrosis

Route:
Interventional/ Implantation

Note:
Live cultured osteoblasts indicated for bone repair and regeneration that stop progression of avascular necrosis. Over 400 pateints treated with GEM106. Potential label extension to different indications. This product has been granted Orphan Designation by the US FDA & EMA.
問合せ
19/09/24 GEM105 Viscosupplementation Knee osteoarthritis Intra-articular Polysaccharide
NDA application Cross-linked sodium hyaluronate hydrogel with sodium hyaluronate fluid. Long lasting and sustainbale efficacy due to unique rheology of the cross-linked hydrogel. Injected only once and single injection shows comparable efficacy to a multiple-injection treatment. Phase-III clinical trial has been finished and NDA application has been submitted. 問合せ
19/09/12 GEM104 Interleukin-1 beta inhibition Refer to Note Oral Small molecule
Preclinical Indication:
Various types of colitis (IBD, immune-related and chemotherapy-induced colitis)

Note:
-A known approved drug molecule developed for new therapeutic indications of treating and alleviating symptoms of various types of colitis.
-Showed greater pharmacological effects than the reference drug, mesalazine, in reducing inflammatory colon swelling and intestinal ulceration, while restoring damaged intestinal membrane.
-One of few products capable of repairing damaged intestine membrane caused by colitis.
-Synergistic effect via different mechanism of actions, can provide greater medical benefits to patients suffering from IBD or various types of colitis caused by cancer treatment with chemo- or immuno-therapy.
問合せ
19/09/03 GEM103 Iron chelator Refer to Note Oral Small molecule
Phase 2 ready for TBI and Phase 1 ready for AMD Indication:
Neurodegenerative and ophthalmologic diseases including traumatic brain injury (TBI) and AMD as lead indications. Additional indications in PD and ALS

Note:
Novel oral iron chelator with excellent PK and ability to penetrate the brain and retina. Non-protein bound or "free" iron has been demonstrated to be deeply involved in neurodegenerative and ophthalmologic diseases, yet optimal chelators are not available. GEM103 efficiently removes free iron from the brain and retina. Biomarkers to guide drug development are available for both TBI and AMD. Phase 1 trials have been completed for transfusion-related iron-overload. Chronic toxicology completed.
問合せ